Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (241-250 of 377) with videos related to

Pageof 38
Sort By:
Breast (Edinburgh, Scotland)|October 12, 2022
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 studyMattea Reinisch, Michael Untch, Rolf Mahlberg, et al.
Breast Care (Basel, Switzerland)|December 5, 2019
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)Diana Lüftner, Ingo Bauerfeind, Michael Braun, et al.
JAMA Oncology|February 18, 2021
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical TrialOtto Metzger Filho, Daniel G Stover, Sarah Asad, et al.
Geburtshilfe Und Frauenheilkunde|March 14, 2022
Correction: Update Breast Cancer 2021 Part 5 - Advanced Breast CancerDiana Lüftner, Florian Schütz, Elmar Stickeler, et al.
Cancers|February 15, 2022
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto TrialBernd Gerber, Andreas Schneeweiss, Volker Möbus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto TrialPeter A Fasching, Christopher Szeto, Carsten Denkert, et al.
Annals of Surgical Oncology|July 28, 2019
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized TrialsDavid Krug, Bianca Lederer, Fenja Seither, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2021
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapyJenny Furlanetto, Volker Möbus, Andreas Schneeweiss, et al.
Geburtshilfe Und Frauenheilkunde|September 16, 2022
Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA studySteffi Hartmann, Thorsten Kühn, Michael Hauptmann, et al.
Geburtshilfe Und Frauenheilkunde|February 16, 2022
Update Breast Cancer 2021 Part 4 - Prevention and Early StagesChristoph Thomssen, Tanja N Fehm, Elmar Stickeler, et al.
Pageof 38

Showing results (241-250 of 377) with videos related to

Sort By:
Pageof 38
Breast (Edinburgh, Scotland)|October 12, 2022
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 studyMattea Reinisch, Michael Untch, Rolf Mahlberg, et al.
Breast Care (Basel, Switzerland)|December 5, 2019
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)Diana Lüftner, Ingo Bauerfeind, Michael Braun, et al.
JAMA Oncology|February 18, 2021
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical TrialOtto Metzger Filho, Daniel G Stover, Sarah Asad, et al.
Geburtshilfe Und Frauenheilkunde|March 14, 2022
Correction: Update Breast Cancer 2021 Part 5 - Advanced Breast CancerDiana Lüftner, Florian Schütz, Elmar Stickeler, et al.
Cancers|February 15, 2022
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto TrialBernd Gerber, Andreas Schneeweiss, Volker Möbus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto TrialPeter A Fasching, Christopher Szeto, Carsten Denkert, et al.
Annals of Surgical Oncology|July 28, 2019
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized TrialsDavid Krug, Bianca Lederer, Fenja Seither, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2021
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapyJenny Furlanetto, Volker Möbus, Andreas Schneeweiss, et al.
Geburtshilfe Und Frauenheilkunde|September 16, 2022
Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA studySteffi Hartmann, Thorsten Kühn, Michael Hauptmann, et al.
Geburtshilfe Und Frauenheilkunde|February 16, 2022
Update Breast Cancer 2021 Part 4 - Prevention and Early StagesChristoph Thomssen, Tanja N Fehm, Elmar Stickeler, et al.
Pageof 38